Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation

Sai Ravi Kiran Pingali, Michelle A Mathiason, Steven D Lovrich, Ronald S Go

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.

Original languageEnglish (US)
Pages (from-to)E25-9
JournalClinical Lymphoma and Myeloma
Volume9
Issue number5
DOIs
StatePublished - Oct 2009

Keywords

  • Adult
  • Fusion Proteins, bcr-abl
  • Humans
  • Janus Kinase 2
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Myeloproliferative Disorders
  • Phlebotomy
  • Risk Factors
  • Translocation, Genetic
  • Case Reports
  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation'. Together they form a unique fingerprint.

Cite this